To determine whether hemodynamic changes can modulate insulin action in vivo, we administered angiotensin II (A,,) to normal men under three separate, euglycemic conditions. First, in the presence of physiological hyperinsulinemia (-115 5,U/ml), infusion of A,, at rates of 2, 10, and 20 ng/min per kg caused significant elevations of blood pressure, whole-body glucose clearance, and plasma insulin concentrations in an Al, dose-dependent manner. Second, in the presence of plasma insulin concentrations that stimulate glucose transport maximally (-5,000 ,U/ml), A,, infusions increased whole-body glucose clearance without enhancing glucose extraction across the leg.
Introduction
Resistance to insulin-mediated glucose disposal is a characteristic ofsome patients with essential hypertension (1) (2) (3) (4) (5) (6) (7) . While a large body of evidence from other disease states indicates that insulin resistance may occur at the level of insulin-sensitive cells (8) (9) (10) , the mechanisms responsible for insulin resistance in hypertensive individuals remain to be determined. Several recent studies indicate that insulin action in the intact organism may be regulated at steps proximal to insulin-mediated glucose uptake by cells. For example, Yang et al. (1 1) reported that transcapillary transport of insulin from plasma to interstitial fluid is rate limiting for insulin-mediated glucose uptake in dogs. Furthermore, Laasko et al. (12) (13) (14) and Anderson et al. (15) reported that stimulation of glucose uptake by insulin in humans is associated with, and perhaps partially determined by, an increase in blood flow to insulin-sensitive tissues. While the hemodynamic actions of insulin per se remain controversial (16) , the data of Laasko et al. (12) (13) (14) and Anderson et al. (15) prompted us to postulate that vasopressors might modulate insulin action in humans through hemodynamic mechanisms. If proven, that hypothesis could be relevant to wholebody insulin sensitivity in different forms of hypertension. To test our hypothesis, we measured the effects of a vasopressor, angiotensin II (A,,),' on whole-body glucose utilization, leg glucose extraction, and leg blood flow during hyperinsulinemic, euglycemic clamps in normal men. Our results indicate that A,, alters insulin action in vivo through a hemodynamic mechanism.
Methods

Subjects
Studies were performed on healthy Caucasian and black men ranging in age from 30 to 50 yr and in body mass index (BMI) from 20 to 36 kg/m2. All subjects gave written, informed consent for participation in the study, which was approved by the Research Committee of the Los Angeles County, University ofSouthern California (LAC+USC) Medical Center.
Protocols
The effect of Al, on glucose metabolism was examined in three studies in which A,, was administered during the last 90 min of270-min euglycemic clamps or sham insulin infusions. In the first study (A,, dose-response study), Al, was infused at three different doses during euglycemic clamps performed at physiological hyperinsulinemia. In the second study (maximum insulin study), A,, was infused in the face of hyperinsulinemia that stimulates glucose utilization maximally in normal men (12) (13) (14) 17) . In the third study (basal insulin study), A Maximum insulin study. Four lean subjects (BMI < 27 kg/m2) participated in this protocol. The glucose clamp procedure was identical to that used for the dose-response study except: (a) insulin was infused at 15 mU/min per kg; (b) potassium phosphate was infused at 15 meq/h during the insulin infusion; (c) only the highest A,, dose pair (5 and 20 ng/min per kg) was given; (d) blood samples were obtained from indwelling right common femoral arterial and venous catheters which were placed at least 1 h before starting insulin and the location ofwhich was verified by ultrasound; (e) blood pressure and heart rate measurements were taken directly from the femoral arterial catheter using a pressure transducer (DTX Pressure Transducer System; Viggo-Spectramed, Oxnard, CA) and digital monitor (model 78353A; HewlettPackard Co., Palo Alto, CA); and (,) blood flow through the left common femoral artery was measured -3.5 cm above the profunda femoris artery by color flow duplex ultrasound scanning (Ultramark 9; Advanced Technologies Laboratories, Bothel, WA) during the basal, insulin-only, and insulin+A1l infusion periods (defined below). During each period, five measurements of the maximum internal diameter of the artery (B-mode ultrasound) and the area under the linear blood velocity curve (pulsed Doppler ultrasound) during two cardiac cycles were taken by a registered vascular technologist who was unaware of the infusions that were being administered. The blood flow rate (crosssectional vessel area X time-averaged blood velocity) was calculated by software provided with the apparatus and a mean ofthe five flow measurements was taken as a single measure offlow for the infusion period. The coefficients of variation for the sets of five flow measurements averaged 12±1% overall and did not vary among infusion periods.
Arterial plasma was used for the glucose clamping procedure and for insulin, tracer, and PAH measurements in this maximum insulin study and the basal insulin study (below). Femoral venous glucose concentrations were measured at 5-min intervals during the basal, insulinonly, and insulin+A,, infusion periods to allow calculation of leg arterio-venous (A-V) glucose concentration differences.
Basal insulin study. The same four subjects who participated in the maximum insulin study underwent a second study, at least 1 wk later, to determine the effects of A,, on glucose utilization in the absence of infused insulin. The protocol was identical to that of the maximum insulin study, except: (a) 0.45% saline was infused instead of insulin; (b) no potassium phosphate was administered; and (c) the volume of 20% dextrose infused during maximum insulin study was replaced by the same volume of 0.45% saline to control for possible effects of volume loading on hemodynamic parameters.
Analytical methods
Glucose was measured by glucose oxidase (Beckman Glucose Analyzer II; Beckman Instruments, Inc., Fullerton, CA). Insulin was measured with a charcoal precipitation radioimmunoassay (18) using guinea pig anti-porcine insulin antibodies and human insulin standards (both from Novo Pharmaceuticals, Danbury, CT). All samples from one subject were run in the same insulin assay. Tritiated glucose concentrations were measured by precipitation of plasma proteins with barium sulfate and zinc chloride, followed by drying of the supernatant, resuspension in water, and counting in a liquid scintillation counter. Counts were corrected for incomplete recovery in each assay, as assessed by the recovery of a known amount of radioactive glucose from pooled human plasma. PAH concentrations were measured chemically (19) ; all samples from one glucose clamp were run in the same PAH assay.
Data analysis
Basal rates of whole-body glucose appearance (Ra) were calculated by the steady-state equation of Steele (20) . Rates of whole-body glucose utilization (Rd; milligrams per minute per kilogram body weight) and endogenous glucose appearance during insulin infusions were calculated by the method of Finegood et al. (21) . Glucose clearance, calculated as Rd/G, where G is the plasma glucose concentration in milligrams per milliliter, was used as a measure ofglucose utilization that is less dependent on glycemia than is Rd (22) . PAH clearance from plasma, measured as an index of renal plasma flow, was calculated as I/C, where I is the infusion rate (milligrams per minute) and C is the plasma concentration (milligrams per milliliter) of PAH.
Data are presented as means±SEM. For analysis of plasma glucose and insulin concentrations, glucose clearance and endogenous production rates, mean arterial pressure (MAP; [systolic pressure + diastolic pressure x 2]/3), heart rate, plasma PAH clearance, femoral arterial blood flow, and femoral A-V glucose concentration differences, an individual mean value for each parameter was calculated during three periods of each glucose clamp: basal (30 min before starting insulin or sham infusion), insulin-only (150-180 min after starting insulin or sham), and insulin+AII (240-270 min after starting insulin or sham).
The individual means were then compared by repeated measures analysis of variance for differences among the three glucose clamps (i.e., clamps performed with different A,, dose pairs) in the dose-response study and for differences among infusion periods in all three studies. Tukey's test was applied post hoc to determine which data differed when analysis of variance revealed a significant difference among clamp protocols or infusion periods. Analysis of linear trends was used to test for Al, dose-dependent differences in MAP and glucose clearance in the insulin+A11 period of the dose-response study. In that study, the effects of Al, on glucose metabolism were similar in lean and obese subjects; data from those two groups were combined for analysis.
Results
Effect of A,, during physiological hyperinsulinemia (Al, doseresponse study). Plasma glucose and insulin concentrations (Table I) did not differ significantly among the three clamp protocols during basal, insulin-only, or insulin+Al1 infusion periods.
Likewise, plasma glucose concentrations did not differ significantly over time in any of the three clamp protocols. Plasma insulin concentrations increased significantly over time in all three protocols. In addition to the expected increase above basal due to the infusion of insulin alone, plasma insulin concentrations increased further during the infusion of A,1 at all dose pairs. The increase in plasma insulin observed during A,, infu- MAP did not differ significantly among the three clamp protocols during the basal or insulin-only periods (Fig. 1, top) . Likewise, no difference in mean, systolic, or diastolic blood pressures was observed between the basal and insulin-only periods of any protocol. A,, increased MAP in all three protocols in parallel with the final A,, doses (P < 0.001 by analysis of linear trends), reflecting the dose-dependent impact of A,, on blood pressure.
Glucose clearance was similar among the three glucose clamp protocols during the basal period (Fig. 1, middle) and clearance increased -2.5-fold during the insulin-only infusion period ofeach protocol. Thus, there were no interprotocol differences in glucose clearance during the infusion of insulin alone. A,, increased glucose clearance by 23, 41, and 72% above the insulin-only period for the lowest, middle, and highest A,, dose pairs, respectively. The final rates of glucose clearance in the three protocols paralleled the final A,, doses (P < 0.01 by analysis of linear trends), suggesting a causal relationship between A,, administration and increased glucose clearance. Insulin suppressed endogenous glucose production in all three protocols (Fig. 1, bottom) and All did not alter glucose production further in any protocol.
Renal plasma flow (Table I) senting only 6.3±1.2% of basal renal plasma flow overall.
Renal plasma flow decreased significantly during each A,, infusion (Table I) . Moreover, the change in renal flow between the insulin-only and insulin+A1l periods was greater for each ofthe two higher A,, dose pairs than for the lowest dose pair (-278±23 and -281±27 vs -166±23 ml/min, respectively; P < 0.001).
Taken together, the findings ofthe A,, dose-response study indicated that under conditions ofphysiological hyperinsulinemia and euglycemia, A,, simultaneously increased blood pressure, plasma glucose clearance, and plasma insulin. By contrast, A,, decreased renal plasma flow and had no detectable impact on the ability of insulin to suppress endogenous glucose production.
Effects of Al, during maximum hyperinsulinemia (maximum insulin study). To determine whether the impact of Al, on glucose clearance was mediated solely through increased plasma insulin concentrations, we performed additional A,, infusions in four subjects after raising plasma insulin to a level at which greater hyperinsulinemia would not be expected to increase whole-body glucose utilization (12) (13) (14) 17) . During those studies, plasma glucose concentrations (Table II) did not differ significantly among basal, insulin-only, and insulin+Al1 infusion periods. The insulin infusions raised plasma insulin concentrations above 4,000 ,U/ml in all four subjects (Table   II) . Addition of Al, at a final rate of 20 ng/min per kg was associated with a 14±3% increase in plasma insulin concentrations, which increased in all four subjects (P < 0.02 vs insulinonly period).
MAP measured directly from the femoral artery (Fig. 2,  top) subjects, from 60±2 beats/min during the basal period to 68±1 beats/min (P < 0.04). A,, had no additional effect on heart rates (70±4 beats/min; P > 0.4 compared with the insulin-only period).
Whole-body glucose clearance (Fig. 2, bottom) increased from 2.7±0.1 ml/min per kg during the basal period to 1 1.0±0.6 ml/min per kg by the end ofthe insulin-only infusion period. A,, increased glucose clearance further, to 14.6±1. 4 clearance in all four subjects by 19-50% (mean, 32±7%). By contrast, A11 did not increase femoral A-V glucose concentration differences significantly (Table II) . In fact, the A-V glucose difference declined by 7-15 mg/dl during A,, infusions in three of the four subjects, while the A-V difference increased by 4 mg/dl in the fourth subject.
Endogenous glucose production was suppressed to rates which were not significantly different from zero (0.45±0.23 mg/min per kg) during insulin infusions alone and Al, did not alter glucose production rates further (-0.59±0.30 mg/min per kg).
Femoral arterial blood flow (Fig. 3, top) did not differ significantly between the basal and insulin-only infusion periods. Administration of Al, increased femoral flow in all four subjects by 81±14% (range 49-117%) above the insulin-only period (P < 0.001). Renal plasma flow (Fig. 3, bottom) increased above basal in all subjects during the infusion of insulin alone (P < 0.01 vs basal period) and renal flow decreased to levels below basal in all subjects during the A,, infusions (P < 0.01 vs insulin-only and basal periods).
Effect ofA1 in the absence ofinfused insulin (basal insulin study). Plasma glucose and insulin concentrations fell slightly but significantly in fasting subjects during the 390-min study (P < 0.002 for each; Table II ). However, glucose turnover did not change significantly during the study, despite the fact that A,, administration during the final 90 min increased the MAP by 38±3 mmHg. That increase was significantly greater than the 20±3 mmHg rise in MAP observed when Al, was infused at the same rate during maximum hyperinsulinemia (P = 0.03). A,, infusions had no effect on femoral A-V glucose concentration differences in the face ofbasal insulin levels (Table II) . Femoral arterial blood flow did not change during the saline infusions (Fig. 3) but increased during Al, infusions in all four subjects by 34±10% (range 18-62%). This increase in flow was less than the increase observed when A,, was infused during maximum hyperinsulinemia (81±14%), although the difference between studies was of borderline statistical significance (P = 0.06). Renal plasma flow was unchanged during saline infusions but declined significantly during Al, infusions (Fig. 3) . The change in renal flow was less than the change observed when Al, was given during maximum insulin infusions (-228±37 vs -296±44 ml/min, respectively; P < 0.01). A,,. To determine whether the increased glucose clearance observed during A,, infusions was purely a result ofthe increased plasma insulin concentrations, we tested the effects of A,, on glucose utilization in the presence of insulin concentrations that have been shown to stimulate glucose uptake maximally in vivo (12) (13) (14) 17) . In that setting, an increase in plasma insulin would not be expected to increase whole-body glucose clear- (14) . In fact, we did for insulin-mediated vasodilation (12) (13) (14) (15) 32 (12) , respectively. The wide variation in flow rates among studies reflects the difficulty of measuring peripheral blood flow in humans, along with the fact that there is no universally accepted method with which to make such measurements. However, three pieces ofevidence suggest that any overestimation of flow in our study did not lead to erroneous conclusions about the effects of A,, on femoral blood flow. First, review of the photographs of blood velocity profiles from our subjects revealed a pattern of increased forward flow in late diastole during the A,, infusions. This finding is consistent with redistribution of flow from high resistance vascular beds (e.g., renal and splanchnic beds) to lower resistance beds in the legs during diastole. Second, our blinded study design and the stability of femoral blood flow measurements during the basal and sham infusion periods (Fig. 3) Although no direct extrapolation can be made from our findings during acute insulin and A,, infusions to chronic effects of Al, on glucose metabolism, our results suggest that hypertensive conditions characterized by activation ofthe reninangiotensin system will not be associated with resistance to insulin-mediated glucose disposal. Most published data from patients with essential hypertension neither support nor refute that suggestion, since the renin-angiotensin system generally has not been characterized in studies of insulin action in human hypertension. However, our own data (40) and those of Kotchen et al. (41) from rats, and existing data from humans (42) , indicate that one form of high-renin hypertension, renovascular hypertension, is associated with normal or enhanced insulin action on glucose metabolism. Those data, together with the findings of this study, suggest that the status of the renin-angiotensin system is one factor that could contribute to the inconsistent association between hypertension and insulin resistance in humans and experimental animals (40) (41) (42) (43) . In summary, we have shown that acute administration of Al, to normal men during euglycemic hyperinsulinemia increases whole-body glucose utilization. The effect appears to result from hemodynamic actions of Al, rather than from a direct effect of Al, to stimulate glucose transport by cells. Our findings indicate that vasopressor agents can modify insulin action through hemodynamic mechanisms. Furthermore, the data suggest that characterization ofthe renin-angiotensin system may be important in studies of the relationship between hypertension and insulin resistance.
